"MAP Kinase Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44 kDa mitogen-activated protein kinase kinase with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048370
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.200 D08.811.913.696.620.682.725.200.200 D12.644.360.440.200 D12.776.476.440.200
|
| Concept/Terms |
MAP Kinase Kinase 2- MAP Kinase Kinase 2
- Kinase Activator Kinase MEK2
- MAPK-ERK Kinase 2
- MAPK ERK Kinase 2
- MAP2K2 Protein
- MAPK Extracellular Signal-Regulated Kinase 2
- MAPK Extracellular Signal Regulated Kinase 2
- Mitogen-Activated Protein Kinase Kinase 2
- Mitogen Activated Protein Kinase Kinase 2
- MEK-2 (MAPK Extracellular Signal-Regulated Kinase 2)
- MAPK Kinase 2
- MEK2 (MAPK Extracellular Signal-Regulated Kinase 2)
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 2".
This graph shows the total number of publications written about "MAP Kinase Kinase 2" by people in this website by year, and whether "MAP Kinase Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 2" by people in Profiles.
-
Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, Aplin AE. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma. Cancer Res. 2022 07 18; 82(14):2625-2639.
-
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.
-
Allanson JE, Anner?n G, Aoki Y, Armour CM, Bondeson ML, Cave H, Gripp KW, Kerr B, Nystrom AM, Sol-Church K, Verloes A, Zenker M. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):129-35.
-
Orsini MJ, Krymskaya VP, Eszterhas AJ, Benovic JL, Panettieri RA, Penn RB. MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. Am J Physiol. 1999 09; 277(3):L479-88.